Abeprazan

Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].

Product Specifications

CAS Number

[1902954-60-2]

Product Name Alternative

DWP14012; Fexuprazan

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/abeprazan.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CNCC1=CN(S(=O)(C2=CC=CC(F)=C2)=O)C(C3=CC=C(F)C=C3F)=C1OC

Molecular Formula

C19H17F3N2O3S

Molecular Weight

410.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48 (2) :206-218.